Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etrasimod for Primary and Secondary Prevention of Pouchitis (ESPIRIT)
NCT07486921Phase 2Recruiting
- Sponsor
- MAIA Biotechnology
- Start
- Jul 2026
- Primary completion
- Feb 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in pouchitis comparing etrasimod with Placebo (2 arms). Primary endpoint: Proportion of participants with at least 1 episode of acute pouchitis at 48 weeks. Started Jul 2026; status: recruiting.
02
Drugs
etrasimod
03
Conditions
pouchitis
Beyond the preview
Go deeper on NCT07486921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07486921.